Search Results for keywords:"controlled substances"

LTS Therapy Systems, LLC is seeking to become a registered importer of certain controlled substances for research and development purposes. The Drug Enforcement Administration (DEA) is asking for public comments or objections to this application by April 7, 2025. Comments must be submitted electronically through the Federal eRulemaking Portal. The company is not permitted to import these substances for commercial sale, and any registration approval will align with legal requirements.

The Drug Enforcement Administration (DEA) has decided to revoke John Stanton, M.D.'s DEA registration because his medical license in Tennessee was revoked, meaning he can't legally handle controlled substances in the state. An Order to Show Cause was issued previously, suggesting the removal of his DEA Certificate of Registration, as he didn't request a hearing, leading to a default judgment. As a result, the DEA has also denied Dr. Stanton's pending applications for any new registration in Tennessee. This decision was signed by the Acting Administrator of the DEA and will take effect on May 21, 2025.

The Drug Enforcement Administration (DEA) is notifying the public of an application from JW Colorado, LLC, to be registered as a bulk manufacturer of marihuana, a controlled substance listed under schedule I. The DEA will evaluate the application along with others under regulations meant to ensure that the growth of marihuana is for legitimate scientific and medical research purposes. Written comments or objections to this proposed registration must be submitted by April 19, 2021, and the evaluation will ensure compliance with all relevant laws and safeguards against misuse.

Siemens Healthcare Diagnostics Inc. has submitted an application to the Drug Enforcement Administration to become a bulk manufacturer of certain controlled substances. The company intends to use these substances to produce products that are exempt from DEA regulations. Individuals or existing registered manufacturers can express their support or objections in writing by March 15, 2021, or request a hearing regarding this application by the same date.

Sigma Aldrich Research Biochemicals, Inc. has applied to the Drug Enforcement Administration (DEA) to become registered as a bulk manufacturer of controlled substances. The public is invited to submit comments or objections and request a hearing by April 26, 2021. The application was submitted on December 17, 2020, and aims to manufacture reference standards of certain controlled substances. Comments should be sent to the DEA at the address provided in the notice.

Patheon API Services, Inc. has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. They intend to use these substances as reference standards in research and development for API Manufacturing, and not for any commercial sales. People affected by this application can submit comments or request a hearing by April 28, 2025. All comments must be submitted electronically through the Federal eRulemaking Portal.

Meridian Medical Technologies, LLC has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. The company plans to import these substances solely for analytical purposes and has no authorization for other activities involving these drugs. The DEA is accepting public comments or objections to this application until April 14, 2025, and has outlined procedures for submitting these electronically via regulations.gov. Requests for a hearing regarding the application must also be submitted by the same date to designated DEA offices in Springfield, Virginia.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Linwood A. Starks, D.V.M., proposing to revoke his Certificate of Registration because he is not authorized to handle controlled substances in Texas due to the suspension of his veterinary license. Starks requested a hearing but failed to respond to the allegations, leading to a termination of proceedings and his default. As a result, the DEA Administrator decided to revoke his registration and deny any future applications, as maintaining a DEA registration requires state authorization to handle controlled substances. This decision takes effect on April 21, 2025.

Chattem Chemicals has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of controlled substances. The application, filed on July 20, 2020, lists substances like Marihuana and Tetrahydrocannabinols, which the company plans to create synthetically for distribution and sale. Interested parties can submit comments or request a hearing on this application by April 26, 2021. Written comments should be sent to the DEA in Springfield, Virginia.

The Drug Enforcement Administration (DEA) has proposed a new rule to allow healthcare practitioners to prescribe controlled substances via telemedicine, without needing an in-person exam, through a Special Registration framework. This framework permits three types of special registrations: Telemedicine Prescribing Registration for Schedule III-V drugs, Advanced Telemedicine Prescribing Registration for Schedule II-V drugs for certain specialists, and Telemedicine Platform Registration for online platforms to dispense these drugs. These changes, which aim to expand patient access while safeguarding against drug abuse, also require practitioners to perform additional prescription checks and comply with detailed reporting and recordkeeping. Public comments on this proposal are welcome before final implementation.